Hudson Bay Capital Management’s ADMA Biologics ADMA Stock Holding History

Hudson Bay Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-13,636	Closed	-$61.6K	–	715
2023 Q4	$61.6K	Hold	13,636	–	–	﹤0.01%	588
2023 Q3	$48.8K	Hold	13,636	–	–	﹤0.01%	647
2023 Q2	$50.3K	Sell	13,636 -592,847	-98%	-$2.2M	﹤0.01%	680
2023 Q1	$2.01M	Sell	606,483 -1,056,299	-64%	-$3.65M	0.02%	525
2022 Q4	$6.45M	Sell	1,662,782 -354,483	-18%	-$1.09M	0.07%	279
2022 Q3	$4.9M	Sell	2,017,265 -133,307	-6%	-$320K	0.04%	430
2022 Q2	$4.26M	Sell	2,150,572 -150,000	-7%	-$295K	0.03%	496
2022 Q1	$4.21M	Buy	+2,300,572	New	+$3.59M	0.06%	432
2020 Q4	–	Sell	-110,000	Closed	-$263K	–	584
2020 Q3	$263K	Sell	110,000 -135,000	-55%	-$370K	﹤0.01%	481
2020 Q2	$717K	Buy	+245,000	New	+$704K	0.01%	395

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hudson Bay Capital Management's ADMA Position: Q1 2024 in Review

Hudson Bay Capital Management sold out of ADMA Biologics (ADMA) in Q1 2024, closing a stake of 13,636 shares — an estimated $61.6K sold.

Hudson Bay Capital Management first reported a position in ADMA in Q2 2020 and held it in 10 quarters. The position peaked at $6.45M in Q4 2022. 214 funds tracked by Wall St. Rank hold ADMA as of Q1 2024.

Hudson Bay Capital Management reported no remaining ADMA Biologics position as of Q1 2024 after selling out during the quarter.
Hudson Bay Capital Management sold 13,636 ADMA Biologics shares in Q1 2024, an estimated $61.6K.
Hudson Bay Capital Management first reported a position in ADMA Biologics in Q2 2020 and held it in 10 quarters.
Hudson Bay Capital Management's ADMA Biologics position peaked at $6.45M in Q4 2022.
214 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2024.

Based on Hudson Bay Capital Management's 13F filing for Q1 2024, filed 15 May 2024.